Alterations in the cyclin-dependent kinase (CDK)-retinoblastoma (RB) machinery disrupt cell-cycle regulation and are being targeted in drug development. To understand the cancer types impacted by this pathway, we analyzed frequency of abnormalities in key cell-cycle genes across 4,864 tumors using nextgeneration sequencing (182 or 236 genes; Clinical Laboratory Improvement Amendments laboratory). Aberrations in the cellcycle pathway were identified in 39% of cancers, making this pathway one of the most commonly altered in cancer.
Introduction
The cyclin D-cyclin-dependent kinase (CDK)-retinoblastoma (RB) pathway is a key gatekeeper for the G 1 phase of the cell cycle. Aberrations in the cell-cycle pathway have been implicated in human cancer that leads to tumor proliferation, chromosomal instability, and attenuation of genomic integrity (1) (2) (3) .
The RB tumor suppressor protein is crucial in regulating the G 1 phase. The G 1 phase is also controlled by the cyclin D and CDK4/6 complex, leading to phosphorylation of the RB protein and subsequent E2F-mediated transcription of target genes that are required for G 1 cell-cycle progression (4) (5) (6) . Recent literature suggests that the cyclin D1 and CDK4/6 complex adds just one phosphate group to the RB (out of 14 different phosphatebinding sites), and subsequent phosphate groups are added by the cyclin E and CDK2 complex, to further hyperphosphorylate the RB protein before entering into the next phase of cell cycle ( Fig.  1 ; ref. 7) . This pathway can be altered through multiple mechanisms, including loss of RB1, increased signaling through CDK4/6 amplification, aberrations in CCND1/CCNE1, or inactivation of pathway inhibitors including CDKN2A/B (5, 6) .
Alterations in the cell-cycle pathway have been described in multiple cancers (8) (9) (10) (11) (12) and are associated with poorer clinical outcome in some tumor types (13) (14) (15) , including acute lymphoblastic leukemia (9) , ovarian (10) , colon cancer (12) , and medulloblastoma (11) .
To overcome cyclin pathway abnormalities in cancers, there are several inhibitors in clinical trials, with varying selectivity for specific members of the CDK family (2) . Among them, palbociclib (PD0332991), a potent and selective CDK4/6 inhibitor, demonstrated prolonged progression-free survival (PFS) in patients with hormone receptor-positive, Her2-negative metastatic breast cancer, in combination with the hormone modulator letrozole, as compared with letrozole alone [PALOMA-1 trial, median PFS of 20.2 vs. 10.2 months, respectively (P ¼ 0.0004); ref. 16 ]. These observations led to accelerated FDA approval in February 2015. Additional CDK4/6 inhibitors are in clinical trials, including LEE011 (17) , abemaciclib (LY-2835219; ref. 4) , and the CDK1/2/5/9 inhibitor dinaciclib (MK-7965, formerly SCH-727965; refs. 18, 19) .
With novel promising CDK inhibitors in clinical trials (4, (16) (17) (18) (19) , the comprehensive analysis of cell-cycle gene aberrations among diverse cancer types is of interest. Next-generation sequencing (NGS) technology makes rapid and accurate identification of these aberrations feasible. Herein, we report the molecular characteristics of CCND1, CCND2, CCND3, CDK4/ 6, CCNE1, CDKN2A/B, and RB1 in 4,864 patients with diverse cancers interrogated by NGS.
Materials and Methods

Patients
We investigated the CCND1/2/3, CDK4/6, CCNE1, CDKN2A/B, and RB1 aberration status of patients with diverse malignancies that were referred for NGS from December 2011 to November 2013 (N ¼ 4,864; Table 1 and Supplementary Tables S1  and S2 ).
Tissue samples and mutational analysis
We collected sequencing data from 4,864 cancers whose formalin-fixed, paraffin-embedded (FFPE) tumor samples were submitted to a Clinical Laboratory Improvement Amendments-certified laboratory for genomic profiling (Foundation Medicine). Samples were required to have a surface area !25 mm 2 , volume !1 mm 3 , nucleated cellularity !80%, and tumor content !20% (20) . The methods used in this assay have been validated and previously reported (20) (21) (22) . Briefly, 50 to 200 ng of genomic DNA was extracted and purified from the submitted FFPE tumor samples. This whole-genome DNA was subjected to shotgun library construction and hybridization-based capture before paired end sequencing on the Illumina HiSeq2000 platform. Hybridization selection is performed using individually synthesized baits targeting the exons of 182 or 236 cancer-related genes and the introns of 14 or 19 genes frequently rearranged in cancer. Sequence data were processed using a customized analysis pipeline (20) . Sequencing was performed with an average sequencing depth of coverage greater than 250Â, with >100Â at >99% of exons. This method of sequencing allows for detection of copy number alterations, gene rearrangements, and somatic mutations with 99% specificity and >99% sensitivity for base substitutions at !5 mutant allele frequency and >95% sensitivity for copy number alterations. A threshold of !8 copies for gene amplification with !6 copies considered equivocal (except for ERRB2, which is considered equivocally amplified with !5 copies) was used. Synonymous mutations were not included in the analysis. Also of note, promoter/enhancer regions for the CDKN2A/B and RB1 loci were not interrogated, and only coding regions were evaluated in the current report. The submitting physicians provided specification of tumor types. The database was deidentified with only diagnosis available. NGS data were collected and interpreted by N-of-One, Inc. For this study, the dataset of 4,864 sequenced tumors was queried for alterations in CCND1, CCND2, CCND3, CDK4/6, CCNE 1, CDKN2A/B, and RB1 genes. This study and data analysis herein was performed in accordance with UCSD IRB guidelines.
cBio Cancer Genomics Portal data
Publicly available datasets containing genomic information from a diverse array of cancer types were investigated for cell-cycle pathway genes (CCND1, CCND2, CCND3, CDK4/6, CCNE 1, CDKN2A/B, and RB1) using cBio Cancer Genomics Portal data (cBioPortal; http://cbioportal.org, March 2016) to compare with the current study (see Supplementary Methods for additional information; refs. 23, 24) .
Statistical analysis
Descriptive statistics were used to summarize the baseline patient characteristics. The Fisher exact test was used to assess the association between categorical variables. All tests were two sided. Statistical analyses were carried out using SPSS version 22.0.
Results
Overview of frequency of alterations in the key cell-cycle pathway genes (CCND1, CCND2, CCND3, CDK4/6, CDKN2A/B, CCNE1, and RB1) Among the 4,864 patients, the most common cancers were breast (10.4%) and lung adenocarcinoma (8.4%; Table 1 Fig. 3 ; Table 1 ]. Overall, the frequencies of cell-cycle pathway aberrations among cancer diagnoses from our current report were similar to those found in the cBioPortal data (Fig. 4) . Tables S1 and S2 ]. Overall, the results from the cBioPortal data were similar, with 7.8% (466/6,009) of cancer cases having CCND1 aberrations ( Supplementary Fig. S2A ). Fig. S2C ).
CCND2
CDK4. CDK4 amplification was seen in 3.2% (156/4,864) of all cancer types. CDK4 amplification was most commonly found in neuroblastoma [17.9% (5/28)], followed by glioblastoma [11.9% (10/84); Supplementary Fig. S1D ; Supplementary Tables  S1 and S2 ]. According to the cBioPortal, CDK4 aberrations were also seen in 3.2% (191/6,009) of cancer cases ( Supplementary  Fig. S2D ). As neuroblastoma data in cBioPortal only reflect mutations and not amplification, we are unable to directly compare cBioPortal alterations with our incidence of CDK4 amplification in neuroblastoma. However, CDK4 amplification was seen in 16.7% (47/281) of glioblastoma cases, which is similar to the incidence in our cases ( Supplementary Fig. S2D ). 
Abbreviations: GIST, gastrointestinal stromal tumor; HNSCC, head and neck squamous cell carcinoma; NSCLC, non-small cell lung cancer; SCC, squamous cell carcinoma; SCLC, small cell lung cancer. Tables S1 and  S2 ]. As opposed to CDKN2A/B aberrations, CDKN2C alterations were rare, seen in only 0.25% (12/4,864) of cases (Supplementary Table S2 ). According to the cBioPortal, CDKN2A/B was aberrant in 18.0% (1,084/6,009) of cases, with 44.8 % (13/29) of cutaneous SCC harboring CDKN2A/B aberrations; these data are similar to the observations in the current report ( Supplementary Fig. S2F ). Tables S1 and S2 ]. According to cBioPortal, CCNE1 aberrations were also seen in 5.0% (303/ 6,009) of cancer cases (Supplementary Fig. S2G ).
RB1. Aberrations in the RB1 tumor suppressor gene were documented in 7.6% (369/4,864) of all cancer types. Among 369 cases with RB1 alteration, 53.9% (199/369) harbored at least one nonsense or frameshift alteration, 45.3% (167/369) harbored at least one structural alteration [including loss: 29.0% (107/369), partial loss: 1.9% (7/369), rearrangement: 0.5% (2/369), partial duplication: 0.5% (2/369), amplification: 0.3% (1/369), and splice site alterations: 13.0% (48/369)], and 2.7% (10/369) harbored at least one missense alteration [including inactivating alterations: 1.6% (6/369) and variants of unknown significance: 1.1% (4/369)]. RB1 aberrations were commonly identified in Figure 2 .
Frequencies of alterations in cell-cycle genes. Among 4,864 patients with diverse malignancies, 1,918 (39%) were found to have alterations in cell-cycle pathway (CCND1/2/3, CDK4/6, CDKN2A/B, CCNE1, and Rb1). The most common aberration was in CDKN2A/B (978/1,918; 51%), followed by RB1 (369/1,918; 19%), CCND1 (295/1,918; 15%), CCNE1 (176/1,918; 9%), and CDK4 (156/1,918; 8%). CDK6 (84/1,918; 4%), CCND2 (84/1,918; 4%), and CCND3 (86/1,918; 4%) alterations were relatively uncommon. Fourteen percent (274/1,918) of patients had more than one aberration in the cellcycle pathway. Tables S1 and S2 ]. The data in our current report are similar to the incidence reported in cBioPortal, where 7.6% (456/6,009) of cancer cases have RB1 aberrations. Consistent with our findings, SCLC is the diagnosis most commonly associated with RB1 aberration in the cBioPortal [74.5% (82/110); Supplementary Fig. S2H ].
Distribution of specific gene alterations by cancer type Breast cancers. Forty percent of patients (203/507) with breast cancer had alterations in cell-cycle pathway genes; these alterations were strikingly common in the small subset of patients with metaplastic breast carcinoma [70.6% (12/17); Table 1 Table 1 for complete list of cancer diagnosis with n < 20. Cell-cycle gene aberrations were most commonly seen in patients with glioblastoma (73.8%) and least common in patients with papillary thyroid carcinoma (9.5%). GIST, gastrointestinal stromal tumor; HNSCC, head and neck squamous cell carcinoma. Adenocarcinoma. Among adenocarcinomas, esophageal adenocarcinoma was most commonly associated with alterations in the cell-cycle pathway [56.5% (39/69)], whereas such alterations were least common in colorectal cancer [10.1% (30/ 298); Table 1 and Supplementary Table S1 ].
Coexisting genomic aberrations among cell-cycle gene aberrations
We investigated whether certain cell-cycle gene aberrations were correlated with one another using the Fisher exact test and multivariate logistic regression analysis ( Fig. 5 ; Supplementary  Table S3) . CCND1, CCND2, and CCND3 aberrations were all positively associated with CDK6 aberrations [OR and P values after multivariate analysis: CCND1 and CDK6 (OR ¼ 3.5; Cumulative cell-cycle gene aberrations (CCND1/2/3, CDK4/6, CDKN2A/B, CCNE1, and RB1) between current report and cBioPortal. In the current report, 39.4% (1,918/4,864) of patient samples were found to have aberrations in cell-cycle pathway genes, while it was found in 38.7% (2,326/6,009) from cBioPortal (http://cbioportal.org).
Ã , cBioPortal data available for mutation only. Included cancer diagnoses with cell-cycle gene aberrations in !40% of patients from current report and when cBioPortal data were available for corresponding diagnosis. P < 0.0001); CCND2 and CDK6 (OR ¼ 4.3; P ¼ 0.003); CCND3 and CDK6 (OR ¼ 3.6; P ¼ 0.007); Fig. 5 ; Supplementary Table  S3E] . On the other hand, RB1 mutations/loss were negatively associated with multiple aberrations in the cell-cycle pathway, including CCND1 (OR ¼ 0.25; P ¼ 0.003), CKD4 (OR ¼ 0.10; P ¼ 0.001), and CDKN2A/B (OR ¼ 0.21; P < 0.0001; Fig. 5 ; Supplementary Table S3H ).
Discussion
This study represents a comprehensive overview of aberrations in relevant cell-cycle pathway genes in a large number of cancer tissues interrogated by NGS (N ¼ 4,864) . Overall, 39.4% of cancers (1,918/4,864) had alterations in the key cell-cycle pathway genes, making the CDK/CCND/RB1 axis one of the most frequently disturbed in cancer (Fig. 2) . Our findings were also comparable with the data from cBioPortal (23, 24) , where 38.7 % (2,326/6,009) of cases harbored aberrations in these cell-cycle pathway genes (Fig. 4 and Supplementary Fig. S2 ).
The frequency of cell-cycle pathway aberrations varies by disease, with glioblastoma having the highest rate of abnormalities (73.8%), whereas colorectal adenocarcinoma has a much lower rate (10.1%), consistent with previous reports on smaller numbers of patients ( Fig. 3; refs. 4, 8, 13 ).
Certain cancer diagnoses were significantly associated with different cell-cycle pathway aberrations. For example, esophageal SCC was highly associated with CCND1 aberrations (OR ¼ 14.5; P < 0.0001); gastroesophageal junction carcinoma, with CDK6 aberration (OR ¼ 19.7; P < 0.0001); and SCLC, with RB1 aberration (OR ¼ 21; P < 0.0001; Supplementary Table S3) .
The selective CDK4/6 inhibitor palbociclib has been FDA approved in hormone receptor-positive, Her2-negative metastatic breast cancer. To date, a correlation between cell-cycle gene aberrations and response of breast cancer to palbociclib has not been shown; however, the question remains of interest. Upregulation of CDK4/6 may occur via CDK4 or CDK6 amplification, inactivation of CDKN2A/B, or CCND1 amplification, which subsequently augments phosphorylation and inactivation of RB1 (4, 5) . Meanwhile, resistance to CDK4/6 inhibitors may be mediated by RB1 or CCNE1 aberrations, which subsequently leads to activation of E2F (25, 26) .
In our dataset, among cancers originating from breast, aberrations in cell-cycle pathway were more commonly seen in patients with metaplastic breast cancer when compared with breast cancer patients in general [70.6% (12/17) vs. 40.0% (203/507); Table 1 and Supplementary Table S1 ]. Metaplastic breast cancer is a rare subtype that is typically negative for either estrogen/progesterone receptors or HER2 (27) and thus is usually treated as triple-negative breast cancer. However, women with metaplastic breast cancer experience detrimental clinical outcomes when compared with patients with triplenegative breast cancer, (28) and thus, there is no standard therapy for metaplastic breast cancer. However, recent data suggest susceptibility to a combination of liposomal doxorubicin, bevacizumab, and temsirolimus, perhaps because these tumors also commonly harbor PI3K/AKT/mTOR pathway aberrations (27, 29, 30) . Our results suggest that, for patients with metaplastic breast cancer, an aberrant cell-cycle pathway may be a potential therapeutic target to be considered, with the caveat being that about one third of the anomalies were in the CCNE1 and RB1 gene, which would confer resistance to CDK4/6 inhibitors.
Among patients with lung cancer, frequencies of aberrations in cell-cycle pathway genes were similar between NSCLC [adenocarcinoma, 41 (31) (32) (33) . It is interesting to note that both SCC of lung and SCLC are associated with tobacco exposure, yet the aberration pattern in cell-cycle genes is different.
We have also evaluated whether the same histology among different cancer types shares similar patterns of aberrations (Table 1 and Supplementary Table S1 ). When focusing on cancer with SCC or adenocarcinoma histologies in various cancer types, aberrations in cell-cycle elements occurred frequently, but rates still differed (Table 1) . These results suggest that histologic classification may be further substratified (34) . Of interest in this regard, head and neck and other tumors Table S3 ).
infected with human papilloma virus (HPV) do not generally exhibit cell-cycle pathway abnormalities, whereas HPV-negative tumors do harbor these alterations, which are often associated with TP53 mutations (35) .
Understanding the mutual exclusivity among some genomic aberrations has been therapeutically important. For example, ALK rearrangements, EGFR or KRAS mutations are mutually exclusive in patients with NSCLC (36) . We have reported here a comprehensive analysis of coexisting genetic aberrations and mutually exclusiveness amongst cell-cycle gene aberrations. We observed that RB1 alterations were significantly less frequently associated with CCND1 (OR ¼ 0.25; P ¼ 0.003), CDK4 (OR ¼ 0.10; P ¼ 0.001), and CDKN2A/B (OR ¼ 0.21, P < 0.0001) aberrations (Fig. 5 and Supplementary Table S3H) . Aberrations in CDKN2A/B were also less associated with CDK4 aberrations (OR ¼ 0.20; P < 0.0001; Fig. 5 ; Supplementary  Table S3F ). These data are consistent with previous smaller studies reporting that CDKN2A, CDK4, and RB1 were mutually exclusive in glioblastomas and CDKN2A, CDK6, and RB1 were mutually exclusive in lung adenocarcinomas (37) . In contrast, we have observed that CDK4/6 aberrations were positively associated with CCND 1/2/3 abnormalities ( Fig.  5 ; Supplementary Table S3A-S3E). The latter observations support the notion that CDK4/6 and CCND 1/2/3 cooperate closely for cell-cycle progression. However, RB1 or CDKN2A/B aberrations alone may be sufficient to perturb cell-cycle progression.
There are several limitations to these data. First, the dataset was not clinically annotated; hence, correlation with phenotypic characteristics and outcome was not feasible. Second, methylation status (which could change gene expression) and correlation between gene amplification and protein expression were not evaluated in this study. As we have not evaluated normal tissues, the impact of germline mutations is not addressed. Similarly, as multiple samples were not analyzed from individual cases, we were unable to evaluate intratumoral heterogeneity. Third, the number of cases with each malignancy relied on the number of specimens submitted by physicians for molecular profiling; this introduces the possibility of sample size bias. In this regard, it is important to note that the dataset only included small numbers of hematologic malignancies (Supplementary Table S1 ). This is important because cell-cycle genes may be affected in them as well. For instance, CCND1 (also known as BCL1) is rearranged in about 60 % of mantle cell lymphomas (38) , and translocations are also seen in about 15% to 20% of multiple myeloma specimens (39) . Interestingly, a preliminary study showed activity for the CDK4/6 inhibitor in mantle cell lymphoma (40) . Further study of this family of genes is needed in hematologic malignancies. Fourth, other genes including CDKN2D, RBL1, RBL2, E2F, CCNE2, CCNA1, CCNA2, and CDK2 that are known to influence cellcycle pathway were not evaluated in the current report, and further investigation is required as to their impact. A final limitation of the data was that diagnosis was determined on the basis of the attending physician designation. Yet despite these limitations, this study provides a very large and comprehensive analysis of cell-cycle gene alterations in a wide range of human cancers.
In conclusion, we have interrogated 4,864 patients with cancer and demonstrated that aberrations in cell-cycle pathway genes are extremely common, being discerned in 39% of tissues across cancer types (Figs. 2 and 3) . However, the frequencies and the types of aberrant cell-cycle pathway differ between and within cancer types. Of interest in this regard, we and others have previously shown that patients with metastatic cancer mostly have distinct molecular portfolios, highlighting the heterogeneity of cancer and that matching patients with genomically targeted therapy can have salutary effects (41) (42) (43) (44) (45) (46) (47) . Aberrations in the cell-cycle pathway may also have prognostic value. For instance, it has been reported that cell-cycle pathway gene alterations are independently associated with poor clinical outcomes, including overall survival (13) (14) (15) . Further study will be required to elucidate the impact of each of the diverse cell-cycle pathway genes and their correlation to response with the various inhibitors being deployed in the clinic, including but not limited to palbociclib (PD0332991; ref. 
